Smoking & Zygomatic Implants: The Honest Risk Picture

The implant literature has pointed in the same direction for a long time: smokers experience higher rates of implant failure and of post-operative complications than non-smokers, and smoking is consistently described as one of the significant modifiable patient-level risk factors in implant dentistry. That is the finding. Any clinic or website that tells you smoking makes no difference is either misinformed or hoping you will not check. Smoking is one of the factors weighed in assessing whether you are a candidate.

We are deliberately not printing a percentage. Published figures vary considerably depending on how studies define a smoker, how long patients were followed, which implant sites were involved and how outcomes were measured, and quoting a single tidy number would misrepresent that spread. If you see a specific failure rate for smokers on a clinic website, ask which study it comes from and how a smoker was defined in it.

The mechanisms usually described are not mysterious. Smoking affects blood flow in soft tissue, oxygen delivery to healing wounds, and the local immune response, all of which matter for wound closure and for the process by which bone bonds to an implant surface. It is also associated with more peri-implant bone loss and gum disease over the longer term, which is why the risk does not end once the surgery has healed.

Most of what people read about smoking and implants was written about conventional implants placed in the jaw ridge — often a single tooth. Zygomatic treatment is a different scale of operation, and three features of it make smoking a bigger variable rather than a smaller one.

Sinus proximity. Zygomatic implants pass close to, or through, the maxillary sinus on their route to the cheekbone. Smoking is associated with impaired function of the mucous membrane that lines the airways and sinuses and with a higher background rate of sinus inflammation, and sinus complications are among the recognised risks of zygomatic surgery. Those two facts sit uncomfortably together.

A larger surgical field. A zygomatic protocol involves substantially more soft-tissue elevation and a longer procedure than a single implant, so there is simply more wound to heal and more tissue relying on good blood supply. The clinic protocol we hold describes surgery in the region of two to four hours under general anaesthesia or sedation. Anything that slows soft-tissue healing has more surface area to act on.

Soft-tissue healing around the prosthesis. The long-term health of a full-arch case depends heavily on the soft tissue around the implants staying healthy, because you cannot remove the bridge to clean under it. Smoking is associated with worse peri-implant soft-tissue outcomes, and that risk runs for years, not weeks. Our risks guide covers the complication picture in full.

Almost every clinic that does this work will ask you to stop smoking for a period before surgery and for a period afterwards. What we are not going to do is print a number of weeks, because the figure varies between clinics and between published guidance documents, and inventing a specific one would be exactly the kind of fake precision this site exists to avoid. ``

What is consistent is the shape of the request. Clinics generally want a smoke-free window before surgery, on the basis that some of the effects on tissue oxygenation and airway irritation begin to reverse relatively quickly once you stop, and a longer smoke-free window after surgery, covering the period of active wound healing at minimum. Some clinics extend the request across the whole integration period before the final bridge is fitted. ``

The useful move is therefore not to search for the magic number but to ask your clinic three specific things: how long before, how long after, and what happens if you cannot manage it. A clinic with a considered answer to the third question is telling you something reassuring about how they practise. One that has clearly never thought about it is telling you something too. Our guide to checking a zygomatic surgeon has more questions in that vein.

This is the section where we have to be most careful, because the honest position is that the evidence is less settled than for cigarettes, and pages that state confident conclusions about vaping and implants are outrunning the data.

Vaping. What is reasonably established is that nicotine itself has vascular effects, and that the aerosol involves heat and inhalation at the surgical site. What is not established, to the level of certainty that would let us make a firm statement here, is how vaping compares quantitatively with smoking for implant outcomes — the research is younger and less consistent. The prudent reading, and the one many clinics take, is that vaping is not assumed to be neutral during healing. Ask your surgeon what they advise about it specifically, rather than assuming that switching means the restrictions no longer apply.

Nicotine replacement therapy. Patches, gum, lozenges and sprays deliver nicotine without combustion, tar or heat at the surgical site, which is a meaningful difference from smoking. UK stop-smoking services use these routinely, and whether they suit you around surgery is a question for your GP, pharmacist or stop-smoking adviser together with your surgeon — not something to decide from a web page.

Heated tobacco. Thinner still on implant-specific evidence. Treat any claim of reduced risk in this context as unproven and disclose use to your clinicians.